The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1129
April 29, 2002
View Complete Issue         Table of Contents 2019 
Pantoprazole IV (Protonix IV)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Pantoprazole IV (Protonix IV)
April 29, 2002 (Issue: 1129)
An IV formulation of pantoprazole sodium (Protonix IV - Wyeth-Ayerst), a benzimidazole proton pump inhibitor (PPI), has been approved by the FDA for short-term treatment of Zollinger-Ellison Syndrome (ZES) and gastroesophageal reflux disease (GERD)...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Pantoprazole IV (Protonix IV)
Article code: 1129b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.